Drug intelligence / Profile preview

ExZCell

Development stage: Preclinical
Lead developer: CellPraxis
Modality: RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
Administration: Topical

Overview

ExZCell is a preclinical-stage topical exosome and microRNA (miRNA) platform developed by CellPraxis, a company within the Axis Biotec ecosystem. The platform is designed for applications in cosmetic dermatology, specifically targeting skin barrier dysfunction and transepidermal water loss (TEWL). It leverages the regenerative potential of exosomes to deliver specific miRNAs that modulate biological processes in the skin, aiming to improve skin health and integrity. The development is currently in the R&D phase, focusing on restoring and maintaining the skin's natural barrier function.

Brand names: ExZCell

Beyond the preview

Go deeper on ExZCell.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ExZCell.

Explore the full profile